Cargando…
Targeting Netrin-1 and -4 as a Novel Diagnostic Parameter and Treatment Option for Diabetic Retinopathy
Diabetic retinopathy (DR) is a retinal vascular disorder associated with both type 1 and type 2 diabetes mellitus (DM). It is characterized by specific loss of pericytes, which leads to an augmented blood vessel permeability, and development of new blood vessels (retinal neovascularization). Moreove...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7323811/ https://www.ncbi.nlm.nih.gov/pubmed/32612349 http://dx.doi.org/10.2147/OPTH.S258044 |
_version_ | 1783551840945700864 |
---|---|
author | Zewdie, Kaleab Alemayehu Ayza, Muluken Altaye Amare Tesfaye, Bekalu Yimer, Ebrahim M |
author_facet | Zewdie, Kaleab Alemayehu Ayza, Muluken Altaye Amare Tesfaye, Bekalu Yimer, Ebrahim M |
author_sort | Zewdie, Kaleab Alemayehu |
collection | PubMed |
description | Diabetic retinopathy (DR) is a retinal vascular disorder associated with both type 1 and type 2 diabetes mellitus (DM). It is characterized by specific loss of pericytes, which leads to an augmented blood vessel permeability, and development of new blood vessels (retinal neovascularization). Moreover, stiffening of eye membrane, inflammation, and apoptosis of endothelial cells also lead to damage of the blood–retinal barrier and blindness in most cases unless it’s detected and managed early. Hence, this review was intended to assess the potential roles of Netrin-1 and -4 as new/alternative biomarkers and therapeutic options for DR. Netrin-1 and -4 have been the most known ligands and are well known for their role in neural guidance. DR has both neural and vascular components; therefore, biomarkers used for both neural and vascular retinal tissues are potentially important. According to different experimental and clinical studies, as compared to the normal groups, there was a significant increment in both retinal Netrin-1 and -4 mRNA and protein levels in the retinopathy groups. In addition, exogenous supplementation of these proteins is also used as a therapeutic agent for DR. |
format | Online Article Text |
id | pubmed-7323811 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | Dove |
record_format | MEDLINE/PubMed |
spelling | pubmed-73238112020-06-30 Targeting Netrin-1 and -4 as a Novel Diagnostic Parameter and Treatment Option for Diabetic Retinopathy Zewdie, Kaleab Alemayehu Ayza, Muluken Altaye Amare Tesfaye, Bekalu Yimer, Ebrahim M Clin Ophthalmol Review Diabetic retinopathy (DR) is a retinal vascular disorder associated with both type 1 and type 2 diabetes mellitus (DM). It is characterized by specific loss of pericytes, which leads to an augmented blood vessel permeability, and development of new blood vessels (retinal neovascularization). Moreover, stiffening of eye membrane, inflammation, and apoptosis of endothelial cells also lead to damage of the blood–retinal barrier and blindness in most cases unless it’s detected and managed early. Hence, this review was intended to assess the potential roles of Netrin-1 and -4 as new/alternative biomarkers and therapeutic options for DR. Netrin-1 and -4 have been the most known ligands and are well known for their role in neural guidance. DR has both neural and vascular components; therefore, biomarkers used for both neural and vascular retinal tissues are potentially important. According to different experimental and clinical studies, as compared to the normal groups, there was a significant increment in both retinal Netrin-1 and -4 mRNA and protein levels in the retinopathy groups. In addition, exogenous supplementation of these proteins is also used as a therapeutic agent for DR. Dove 2020-06-25 /pmc/articles/PMC7323811/ /pubmed/32612349 http://dx.doi.org/10.2147/OPTH.S258044 Text en © 2020 Zewdie et al. http://creativecommons.org/licenses/by-nc/3.0/ This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php). |
spellingShingle | Review Zewdie, Kaleab Alemayehu Ayza, Muluken Altaye Amare Tesfaye, Bekalu Yimer, Ebrahim M Targeting Netrin-1 and -4 as a Novel Diagnostic Parameter and Treatment Option for Diabetic Retinopathy |
title | Targeting Netrin-1 and -4 as a Novel Diagnostic Parameter and Treatment Option for Diabetic Retinopathy |
title_full | Targeting Netrin-1 and -4 as a Novel Diagnostic Parameter and Treatment Option for Diabetic Retinopathy |
title_fullStr | Targeting Netrin-1 and -4 as a Novel Diagnostic Parameter and Treatment Option for Diabetic Retinopathy |
title_full_unstemmed | Targeting Netrin-1 and -4 as a Novel Diagnostic Parameter and Treatment Option for Diabetic Retinopathy |
title_short | Targeting Netrin-1 and -4 as a Novel Diagnostic Parameter and Treatment Option for Diabetic Retinopathy |
title_sort | targeting netrin-1 and -4 as a novel diagnostic parameter and treatment option for diabetic retinopathy |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7323811/ https://www.ncbi.nlm.nih.gov/pubmed/32612349 http://dx.doi.org/10.2147/OPTH.S258044 |
work_keys_str_mv | AT zewdiekaleabalemayehu targetingnetrin1and4asanoveldiagnosticparameterandtreatmentoptionfordiabeticretinopathy AT ayzamulukenaltaye targetingnetrin1and4asanoveldiagnosticparameterandtreatmentoptionfordiabeticretinopathy AT amaretesfayebekalu targetingnetrin1and4asanoveldiagnosticparameterandtreatmentoptionfordiabeticretinopathy AT yimerebrahimm targetingnetrin1and4asanoveldiagnosticparameterandtreatmentoptionfordiabeticretinopathy |